...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Medical mycology: official publication of the International Society for Human and Animal Mycology >Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group
【24h】

Risks and outcomes of invasive fungal infections in pediatric allogeneic hematopoietic stem cell transplant recipients receiving fluconazole prophylaxis: a multicenter cohort study by the Turkish Pediatric Bone Marrow Transplantation Study Group

机译：儿科同种异体造血干细胞移植受者的风险和结果接受氟康唑预防的药物：土耳其小儿骨髓移植研究组的多中心队列研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Invasive fungal infections (IFIs) are a major cause of infection-related morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Data from pediatric settings are scarce. To determine the incidence, risk factors and outcomes of IFIs in a 180-day period post-transplantation, 408 pediatric patients who underwent allogeneic HSCT were retrospectively analyzed. The study included only proven and probable IFIs. The cumulative incidences of IFI were 2.7%, 5.0%, and 6.5% at 30, 100, and 180 days post-transplantation, respectively. According to the multivariate analysis, the factors associated with increased IFI risk in the 180-day period post-HSCT were previous HSCT history (hazard ratio [HR], 4.57; 95% confidence interval [CI] 1.42-14.71; P =.011), use of anti-thymocyte globulin (ATG) (HR, 2.94; 95% CI 1.27-6.80; P =.012), grade III-IV acute graft-versus-host-disease (GVHD) (HR, 2.91; 95% CI 1.24-6.80; P =.014) and late or no lymphocyte engraftment (HR, 2.71; 95% CI 1.30-5.62; P =.007). CMV reactivation was marginally associated with an increased risk of IFI development (HR, 1.91; 95% CI 0.97-3.74; P =.063). IFI-related mortality was 1.5%, and case fatality rate was 27.0%. The close monitoring of IFIs in pediatric patients with severe acute GVHD who receive ATG during conditioning is critical to reduce morbidity and mortality after allogeneic HSCT, particularly among those with prior HSCT and no or late lymphocyte engraftment.
机译：侵袭性真菌感染（IFIS）是接受同种异体造血干细胞移植（HSCT）的患者感染相关发病率和死亡率的主要原因。来自儿科设置的数据是稀缺的。为了确定IFIS在移植后180天的发生率，危险因素和结果，回顾性分析了408名接受同种异体HSCT的儿科患者。该研究仅包括证明和可能的IFIS。移植后30,100和180天的IFI累积发病率分别为2.7％，5.0％和6.5％。根据多变量分析，与HSCT后180天期间的IFI风险增加的因素是先前的HSCT历史（危险比[HR]，4.57; 95％置信区间[CI] 1.42-14.71; P = .011 ），使用抗胸腺细胞球蛋白（ATG）（HR，2.94; 95％CI 1.27-6.80; p = .012），III级-4级急性接枝 - 与宿主病（GVHD）（HR，2.91; 95 ％CI 1.24-6.80; p = .014）和晚期或没有淋巴细胞植入（HR，2.71; 95％CI 1.30-5.62; p = .007）。 CMV再激活与IFI发育的风险增加略微相关（HR，1.91; 95％CI 0.97-3.74; P = .063）。 IFI相关的死亡率为1.5％，病例死亡率为27.0％。在调节期间接受ATG的严重急性GVHD的儿科患者的IFIS密切监测对于在同种异体HSCT后降低发病率和死亡率至关重要，特别是具有先前HSCT和NO或晚期淋巴细胞植入的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号